Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"AstraZeneca-CICC Fund","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19\/CD20 CAR-T Cell Therapy for Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellular Biomedicine Group

    Menu

    Cellular Biomedicine Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cellular Biomedicine Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small ...

              Details:

              The collaboration will evaluate Nektar's NKTR-255, a novel IL-15 receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.

              Lead Product(s): NKTR-255,C-TIL051

              Therapeutic Area: Oncology Product Name: NKTR-255

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Nektar Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

              Details:

              Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the treatment R/R DLBCL.

              Lead Product(s): Prizloncabtagene Autoleucel

              Therapeutic Area: Oncology Product Name: C-CAR039

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: $245.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration May 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations

              Details:

              FDA has granted C-CAR039 both RMAT and FTD, based on the result that showed overall response rate of 92.6%, and a complete response rate of 85.2% in relapsed or refractory diffuse large B cell lymphoma.

              Lead Product(s): C-CAR039

              Therapeutic Area: Oncology Product Name: EXP039

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

              Details:

              C-CAR039, an autologous bi-specific CAR-T cell therapy targeting both CD19/CD20 for treatment in adult patients with relapsed/refractory B-cell non-Hodgkin lymphomas. Clinical study results from an ongoing multicenter trial conducted in China have shown 92.6% response rate.

              Lead Product(s): C-CAR039

              Therapeutic Area: Oncology Product Name: EXP039

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies

              Details:

              The financing will largely be used to accelerate the clinical development of the Company's immune-oncology platform specifically, C-CAR039, an anti-CD19/CD20 bispecific CAR-T therapy for the treatment of patients with relapsed or refractory non-Hodgkin lymphoma.

              Lead Product(s): C-CAR039

              Therapeutic Area: Oncology Product Name: EXP039

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: AstraZeneca-CICC Fund

              Deal Size: $120.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CBMG' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy

              Details:

              C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy.

              Lead Product(s): C-CAR066

              Therapeutic Area: Oncology Product Name: C-CAR066

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting

              Details:

              C-TCR055 is CBMG's proprietary clinical lead of TCR-T which specifically recognizes the HLA-A*02:01 restricted AFP158-166 peptide that is highly expressed in hepatocellular carcinoma (HCC) and other solid tumors.

              Lead Product(s): AFP TCR T Cells

              Therapeutic Area: Oncology Product Name: C-TCR055

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellular Biomedicine Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress

              Details:

              Cellular has started to collaborate with Shanghai Ruijin Hospital on a pilot clinical study on inhalation of mesenchymal stem cell exosomes treating severe Novel Coronavirus Pneumonia.

              Lead Product(s): Mesenchymal stem cell exosomes

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY